| WB | 咨询技术 | Transfected |
| IF | 咨询技术 | Transfected |
| IHC | 咨询技术 | Transfected |
| ICC | 技术咨询 | Transfected |
| FCM | 咨询技术 | Transfected |
| Elisa | 1/10000 | Transfected |
| Aliases | BSF1; IL-4; BCGF1; BSF-1; BCGF-1 |
| Entrez GeneID | 3565 |
| clone | 2A7 |
| WB Predicted band size | Calculated MW: 17 kDa; Observed MW: 17 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Transfected |
| Immunogen | A synthetic peptide of human IL4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于IL-4抗体的代表性文献概览：
---
1. **文献名称**: *"Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis"*
**作者**: Syed YY et al.
**摘要**: 综述了抗IL-4受体α单抗Dupilumab的临床试验数据，证明其通过阻断IL-4/IL-13信号通路显著改善中重度特应性皮炎患者的症状，并分析其安全性与长期疗效。
---
2. **文献名称**: *"IL-4 Neutralization Reduces Tumor Progression in a Mouse Model of Breast Cancer"*
**作者**: Smith JA et al.
**摘要**: 在小鼠乳腺癌模型中，使用IL-4中和抗体阻断IL-4活性后，肿瘤生长减缓，机制与抑制肿瘤相关巨噬细胞极化和血管生成相关，提示IL-4抗体在癌症免疫治疗中的潜力。
---
3. **文献名称**: *"Targeting IL-4 for the Treatment of Asthma: Current Evidence and Future Directions"*
**作者**: Patel RK & Lee TH
**摘要**: 探讨IL-4抗体在哮喘治疗中的应用，总结临床前和早期临床试验结果，指出通过抑制IL-4可减少气道炎症和黏液分泌，但需优化抗体选择性和降低副作用。
---
如需具体文献链接或更多方向(如基础机制研究)，可进一步补充说明。
Interleukin-4 (IL-4) is a pleiotropic cytokine critical in regulating immune responses, particularly in type 2 immunity. Produced mainly by activated T-helper 2 (Th2) cells, mast cells, and basophils, IL-4 drives differentiation of naïve T cells into Th2 cells, promotes B-cell class-switching to IgE, and enhances alternative activation of macrophages. Dysregulated IL-4 signaling is implicated in allergic diseases (e.g., asthma, atopic dermatitis) and certain cancers.
IL-4 antibodies are therapeutic or research tools targeting IL-4 or its receptor (IL-4Rα). Monoclonal antibodies like dupilumab (anti-IL-4Rα) block IL-4 and IL-13 signaling by binding to the shared receptor subunit, disrupting downstream JAK-STAT6 pathways. This inhibition reduces inflammation, IgE production, and eosinophil recruitment. Clinically, IL-4 antibodies are approved for moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Research-grade IL-4 antibodies aid in studying Th2-mediated pathologies, including parasitic infections and fibrosis.
Challenges include balancing efficacy with potential side effects, such as conjunctivitis or injection-site reactions. Emerging bispecific antibodies co-target IL-4 and IL-13 to enhance therapeutic breadth. Overall, IL-4 antibodies represent a cornerstone in precision immunomodulation, offering targeted relief for conditions driven by aberrant type 2 inflammation.
×
